VEGFR inhibitor

DRUG CLASS:

VEGFR inhibitor

News alerts, weekly reports and conference planners

Related drugs:

HER-2 amplification	Cholangiocarcinoma	HER-2 amplification	Cholangiocarcinoma	pembrolizumab + lenvatinib + pyrotinib Sensitive: C4 – Case Studies World J Surg Oncol - 4 days (New C4) pembrolizumab + lenvatinib + pyrotinib Sensitive : C4 World J Surg Oncol - 4d	pembrolizumab + lenvatinib + pyrotinib Sensitive: C4 – Case Studies World J Surg Oncol - 4 days pembrolizumab + lenvatinib + pyrotinib Sensitive : C4 World J Surg Oncol - 4 days - (New C4)
SDHB deletion	Gastrointestinal Stromal Tumor	SDHB deletion	Gastrointestinal Stromal Tumor	sunitinib Sensitive: A2 - Guideline NCCN - 2 weeks (New A2) sunitinib Sensitive : A2 NCCN - 2wk	sunitinib Sensitive: A2 - Guideline NCCN - 2 weeks sunitinib Sensitive : A2 NCCN - 2 weeks - (New A2)
DDR	Cholangiocarcinoma	DDR	Cholangiocarcinoma	lenvatinib + toripalimab Sensitive: C3 – Early Trials Signal Transduct Target Ther - 2 weeks (New C3) lenvatinib + toripalimab Sensitive : C3 Signal Transduct Target Ther - 2wk	lenvatinib + toripalimab Sensitive: C3 – Early Trials Signal Transduct Target Ther - 2 weeks lenvatinib + toripalimab Sensitive : C3 Signal Transduct Target Ther - 2 weeks - (New C3)
SPP1 elevation	Hepatocellular Cancer	SPP1 elevation	Hepatocellular Cancer	lenvatinib Resistant: C3 – Early Trials Cancer Commun (Lond) - 2 weeks (New C3) lenvatinib Resistant : C3 Cancer Commun (Lond) - 2wk	lenvatinib Resistant: C3 – Early Trials Cancer Commun (Lond) - 2 weeks lenvatinib Resistant : C3 Cancer Commun (Lond) - 2 weeks - (New C3)
ABCG2 expression	Colorectal Cancer	ABCG2 expression	Colorectal Cancer	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) sunitinib + GF120918 Sensitive : D AACR 2023 - 2wk	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks sunitinib + GF120918 Sensitive : D AACR 2023 - 2 weeks - (New D)
ABCB1 expression	Colorectal Cancer	ABCB1 expression	Colorectal Cancer	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) sunitinib + GF120918 Sensitive : D AACR 2023 - 2wk	sunitinib + GF120918 Sensitive: D – Preclinical AACR 2023 - 2 weeks sunitinib + GF120918 Sensitive : D AACR 2023 - 2 weeks - (New D)
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1	surufatinib Sensitive: A1 - Approval surufatinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1	fruquintinib Sensitive: A1 - Approval fruquintinib Sensitive : A1
KIT mutation	Thymic Carcinoma	KIT mutation	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
No biomarker	Meningioma	No biomarker	Meningioma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2	cediranib Sensitive: A2 - Guideline cediranib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
KIT exon 13 mutation	Melanoma	KIT exon 13 mutation	Melanoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2	lenvatinib Sensitive: A2 - Guideline lenvatinib Sensitive : A2

VEGFR inhibitor

VEGFR inhibitor

Associations(303)

Associations
(303)